1. Arlett P, Kjaer J, Broich K, Cooke E. Real-World Evidence in EU Medicines Regulation: Enabling Use and Establishing Value. Clin Pharmacol Ther. 2021 Nov 19.
     

  2. Bakker E, Hendrikse NM, Ehmann F, van der Meer DS, Llinares Garcia J, Vetter T, Starokozhko V, Mol PGM. Biomarker qualification at the European Medicines Agency: a review of biomarker qualification procedures from 2008 to 2020. Clin Pharmacol Ther. 2022 Feb 9.
     

  3. Bloem LT, Bot RE, Mantel-Teeuwisse AK, van der Elst ME, Sonke GS, Klungel OH, Leufkens HGM, Hoekman J. Pre-approval and post-approval availability of evidence and clinical benefit of conditionally approved cancer drugs in Europe: a comparison with standard approved cancer drugs. Br J Clin Pharmacol. 2021 Nov 15.
     

  4. Candore G, Monzon S, Slattery J, Piccolo L, Postigo R, Xurz X, Strauss S, Arlett P. The Impact of Mandatory Reporting of Non-Serious Safety Reports to EudraVigilance on the Detection of Adverse Reactions. Drug Saf. 2021 Dec 8.
     

  5. Eskola SM, Leufkens HGM, Bate A, De Bruin ML, Gardarsdottir H. Use of Real-World Data and Evidence in Drug Development of Medicinal Products Centrally Authorized in Europe in 2018-2019. Clin Pharmacol Ther. 2021 Oct 24.
     

  6. Flynn R, Plueschke K, Quinten C, Strassmann V, Duijnhoven RG, Gordillo-Marañon M, Rueckbeil M, Cohet C, Kurz X. Marketing Authorization Applications Made to the European Medicines Agency in 2018-2019: What was the Contribution of Real-World Evidence? Clin Pharmacol Ther. 2021 Oct 24.
     

  7. Hekman P, Schefferlie J, Gehring R. Modelling Shows the Negative Impact of Age Dependent Pharmacokinetics on the Efficacy of Oxytetracycline in Young Steers. Frontiers in Veterinary Science. 2022 Jan 28, vol. 8.
     

  8. Ismail RK, van Breeschoten J, Wouters MWJM, van Dartel M, van der Flier S, Reyners AKL, de Graeff P, Pasmooij AMG, de Boer A, Broekman KE, Hilarius DL. Palbociclib dose reductions and the effect on clinical outcomes in patients with advanced breast cancer. Breast. 2021 Nov 17.
     

  9. Maas DPMSM, Wijnans EG, van der Zeijst BAM, Kramers C. COVID-19-vaccins: hoe zit het? [COVID-19 vaccines: the facts]. Ned Tijdschr Geneeskd. 2021 Aug 4.
     

  10. Maliepaard M, Carree W, van Bussel MTJ. Dose selection and tolerability of anticancer agents evaluated by the European Medicines Agency in the period 2015-2020. ESMO Open. 2021 Nov 6.
     

  11. de Meza MM, Ismail RK, Rauwerdink D, van Not OJ, van Breeschoten J, Blokx WAM, de Boer A, van Dartel M, Hilarius DL, Ellebaek E, Bonenkamp HJ, Blank CU, Aarts MJB, van Akkooi ACJ, van den Berkmortel FWPJ, Boers-Sonderen MJ, de Groot JWB, Haanen JB, Hospers GAP, Kapiteijn EW, Piersma D, van Rijn RS, van der Veldt AAM, Vreugdenhil A, Westgeest HM, van den Eertwegh AJM, Suijkerbuijk KPM, Wouters MWJM. Adjuvant treatment for melanoma in clinical practice - Trial versus reality. Eur J Cancer. 2021 Sep 29.
     

  12. Mulder J, van Rossum T, Mariz S, Magrelli A, de Boer A, Pasmooij AMG, Stoyanova-Beninska V. Orphan Medicinal Products for the Treatment of Pancreatic Cancer: Lessons Learned From Two Decades of Orphan Designation. Front Oncol. 2021 Dec 20.
     

  13. Mulder J, Verjans R, Verbaanderd C, Pean E, Weemers J, Leufkens HGM, Pignatti F, de Boer A, Voest EE, Stoyanova-Beninska VV, Pasmooij AMG. Extension of Indication for Authorised Oncology Products in the European Union: A Joint Effort of Multiple Stakeholders. Front Med (Lausanne). 2021 Dec 9.
     

  14. van Riet-Nales, DA, van den Bemt, B, van Bodegom, D, et al. Commentary on the EMA reflection paper on the pharmaceutical development of medicines for use in the older population. Br J Clin Pharmacol. 2022.
     

  15. Schneiderova K, Bere N, Stenver DI, Straus SMJM. Patient Preferences for Rituximab Additional Risk Minimization Measures: Results From an International Online Survey. J Patient Saf. 2021 Oct 4.
     

  16. Schoenmakers DH, Beerepoot S, van den Berg S, Adang L, Bley A, Boelens JJ, Fumagalli F, Goettsch WG, Grønborg S, Groeschel S, van Hasselt PM, Hollak CEM, Lindemans C, Mochel F, Mol PGM, Sevin C, Zerem A, Schöls L, Wolf NI. Modified Delphi procedure-based expert consensus on endpoints for an international disease registry for Metachromatic Leukodystrophy: The European Metachromatic Leukodystrophy initiative (MLDi). Orphanet J Rare Dis. 2022 Feb 14.